A coalition of institutional investors is submitting shareholder proposals to demand several drug makers compile reports about the risks created by high prices and, in some cases, also examine the extent to which pricing strategies propel executive compensation.

The move, which is being led by the Interfaith Center for Corporate Responsibility, is an attempt to go beyond similar efforts in years past that largely — and unsuccessfully — tried to force drug makers to justify and explain their pricing.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy